Recurrent cytokine release syndrome in patients receiving bispecific antibody therapy for multiple myeloma: a case series
Roberta Della Pepa(University of Naples Federico II), Fabrizio Pane(Federico II University Hospital), Carmine Liberatore(Arcispedale Sant'Anna), Mara Memoli(Federico II University Hospital), Bernardo Rossini(Istituto Tumori Bari), Francesco Grimaldi(Federico II University Hospital), Simona Avilia(Federico II University Hospital), Aldo Leone(Federico II University Hospital)
Cited by 1
Related Papers
In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
|Blood|2017|99
Plerixafor Added to Chemotherapy Plus G-CSF Is Safe and Allows Adequate PBSC Collection in Predicted Poor Mobilizer Patients with Multiple Myeloma or Lymphoma
|Transplantation and Cellular Therapy|2011|74
Novel Targeting of Phospho-cMET Overcomes Drug Resistance and Induces Antitumor Activity in Multiple Myeloma
|Clinical Cancer Research|2013|68
Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure
|Journal of Renal Nutrition|2004|61
Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure
|Journal of Renal Nutrition|2004|59